Parkinson's Disease Clinical Trial
— SIAXIOfficial title:
Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
Verified date | January 2018 |
Source | Merz Pharmaceuticals GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of chronic troublesome sialorrhea that occurs as a result of various neurological conditions in adult subjects.
Status | Completed |
Enrollment | 184 |
Est. completion date | November 2016 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Documented diagnosis of the basic neurological condition associated with sialorrhea (as above, (i), (ii) or (iii); with onset at least 6 months before screening). - Chronic troublesome sialorrhea related to parkinsonism or stroke or traumatic brain injury (for at least 3 months) at screening, defined as the presence of all of the following, at screening and at baseline and for at least the 3 months before screening (where retrospective response to questionnaires is impossible, a statement of equivalent severity will suffice): 1. A Drooling Severity and Frequency Scale [DSFS] sum score of at least 6 points and 2. A score of at least 2 points for each item of the DSFS and 3. A score of at least 3 points on the modified Radboud Oral Motor Inventory for Parkinson's Disease [mROMP], Section 'III Drooling', Item A). - A score of at most 2 points on the mROMP Section 'II Swallowing Symptoms' Item A) and a score of at most 3 points on Item C), at screening and at baseline. Exclusion Criteria: - Non-neurological secondary causes of sialorrhea. - Unstable concomitant medication influencing sialorrhea (such as anticholinergics for the treatment of parkinsonism; dosages of these medications must have been stable for at least 4 weeks before study entry, i.e. screening, and must be planned to remain stable during the course of the study. - Recent (i.e., four weeks) drug treatment for sialorrhea. - History of recurrent aspiration pneumonia. - Extremely poor dental/oral condition as assessed by a qualified dentist. - Recent (i.e., one year for sialorrhea, 14 weeks for other indications) treatment with - or known hypersensitivity to - Botulinum toxin, or known hypersensitivity to any ingredient of the study preparation. - Recent (i.e., four weeks) changes in anti-parkinsonian medication. - Previous or planned surgery or irradiation to control sialorrhea. |
Country | Name | City | State |
---|---|---|---|
Germany | Merz investigational site #049172 | Bonn | |
Germany | Merz Investigational Site #049335 | Gera | |
Germany | Merz Investigational Site #049337 | Haag i.OB | |
Germany | Merz Investigational Site #049072 | Munich | |
Germany | Merz Investigational Site #049148 | Munich | |
Germany | Merz Investigational Site #049300 | Nümbrecht | |
Germany | Merz Investigational Site #049303 | Regensburg | |
Germany | Merz investigational site #049348 | Stadtroda | |
Germany | Merz Investigational Site #049143 | Ulm | |
Germany | Merz Investigational Site #049333 | Wolfach | |
Germany | Merz Investigational Site #049302 | Wuerzburg | |
Poland | Merz investigational site #048068 | Bydgoszcz | |
Poland | Merz Investigational Site #048088 | Bydgoszcz | |
Poland | Merz Investigational Site #048029 | Gdansk | |
Poland | Merz investigational site #048074 | Gdansk | |
Poland | Merz investigational site #048078 | Jaworzno | |
Poland | Merz investigational site #048076 | Katowice | |
Poland | Merz investigational site #048077 | Katowice | |
Poland | Merz investigational Site #048067 | Kielce | |
Poland | Merz investigational site #048031 | Krakow | |
Poland | Merz investigational site #048059 | Krakow | |
Poland | Merz Investigational Site #048087 | Krakow | |
Poland | Merz Investigational Site #048022 | Lodz | |
Poland | Merz investigational site #048070 | Lublin | |
Poland | Merz investigational site #048085 | Lublin | |
Poland | Merz investigational site #048072 | Lubon | |
Poland | Merz Investigational Site #048075 | Sandomierz | |
Poland | Merz Investigational Site #048086 | Torun | |
Poland | Merz investigational site #048056 | Warszawa | |
Poland | Merz investigational site #048064 | Warszawa | |
Poland | Merz investigational site #048065 | Warszawa |
Lead Sponsor | Collaborator |
---|---|
Merz Pharmaceuticals GmbH |
Germany, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4 | uSFR was assessed by weighing of dental rolls soaked with saliva over 5 minutes and then procedure was repeated after 30 minutes and the average of the 2 results for flow rate was calculated. | Baseline and Week 4 | |
Primary | MP: Participant's Global Impression of Change Scale (GICS) at Week 4 | The GICS was used to measure the impression of change due to treatment. The response option was a common 7-point Likert scale that ranged from -3 = very much worse to +3 = very much improved and was applicable for participant and caregiver. If the participant was not able to answer then carer's rating was to be recorded instead of participant's rating and the participant's rating was left blank. | Week 4 | |
Secondary | MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 8 and 12 | uSFR was assessed by weighing of dental rolls soaked with saliva over 5 minutes and then procedure was repeated after 30 minutes and the average of the 2 results for flow rate was calculated. | Baseline, Week 8 and 12 | |
Secondary | MP: Global Impression of Change Scale (GICS) at Week 1, 2, 8 and 12 | The GICS was used to measure the investigator's impression of change due to treatment. The response option was a common 7-point Likert scale that ranged from -3 = very much worse to +3 = very much improved and was applicable for participant and caregiver. If the participant was not able to answer then carer's rating was to be recorded instead of participant's rating and the participant's rating was left blank. | Week 1, 2, 8, and 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A |